Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older, of any gender
• People who have been diagnosed with pancreatic cancer (specifically the type that starts in the lining of the pancreatic ducts), confirmed by laboratory testing, and whose cancer has been classified as locally advanced (not yet spread to other parts of the body)
• People whose cancer did not respond to, or who could not tolerate, a standard chemotherapy treatment called AG (having completed at least one full cycle of that treatment)
• People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale called the ECOG score (scores 0 to 2, meaning fully active to capable of limited self-care)
• People whose blood test results show that their immune cells, red blood cells, and platelets are at adequate levels
• People whose liver, kidney, and other organ function test results meet the specific levels required by the trial
• People whose heart function tests (including an ECG and heart pumping measurement) are normal or only mildly abnormal in a way the trial doctor considers not significant
• People who have recovered, or are stable, from side effects of any previous surgery, radiotherapy, chemotherapy, or other cancer treatment, and who are at least 3 weeks past their last treatment
• People who are willing to take part, sign a consent form, and attend follow-up appointments as required

Who may not be able to join:

• People whose pancreatic cancer has spread to other parts of the body (metastatic), or who have previously had a procedure to treat the pancreatic cancer directly (interventional treatment)
• People who have a significant build-up of fluid in the abdomen that requires medical treatment, unless it has been stable for more than 4 weeks after drainage
• People with serious gastrointestinal problems such as bleeding, infection, perforation, blockage, or more than mild diarrhoea
• People whose pain score remains at 4 or higher (on a standard 0–10 scale) even after receiving pain medication
• People who have had another type of cancer within the past 5 years (some exceptions may apply for certain fully cured skin cancers or cancers that have not returned — confirm with trial site)
• People with serious, uncontrolled heart or blood vessel conditions, including severe heart failure, unstable chest pain, a heart attack or stroke within the past 6 months, certain heart rhythm problems requiring treatment, or blood pressure that remains too high despite treatment
• People with active hepatitis B infection at levels above a certain threshold
• People with an active infection or unexplained fever above 38.5°C at the time of joining the trial (some exceptions may apply if the fever is judged to be caused by the tumour — confirm with trial site)
• People who have a known allergy to any of the trial medications or their components, including irinotecan hydrochloride liposome, oxaliplatin, 5-FU, leucovorin, or S-1
• People who are pregnant or breastfeeding
• Women who could become pregnant and have a positive pregnancy test during the screening period (all participants, male and female, are required to use reliable contraception during the trial and for 3 months after the last dose)
• People with other medical or personal circumstances that, in the trial doctor's judgement, could affect their ability to consent, participate fully, or allow the results to be properly assessed
• People whose estimated life expectancy is 3 months or less

Important: Always verify eligibility with the trial site directly before applying.